Merck suspends trial enrollment

SurModics says that Merck informed the company that results reported in a recently published study comparing laser treatment and intravitreal injections of triamcinolone acetonide in patients with diabetic macular edema prompted Merck to reevaluate the design of its Phase IIb clinical trial for I-vation TA. Pending the review, Merck is suspending enrollment of new patients in the Phase IIb clinical trial. The License and Research Collaboration Agreement with Merck continues, and other ongoing development programs with Merck are unaffected. Release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.